12 Sep - 26 Sep 2022Rights issue
Pharmiva is a Swedish femtech company that works for better vaginal health by developing innovative antibiotic-free treatments against vaginal infections.
The company’s first product is Vernivia®, a non-prescription CE-certified vaginal mousse with the indication bacterial vaginosis (BV), a common vaginal infection that affects 1 in 3 women aged 14-49. With Vernivia® vaginal mousse, women get access to an effective treatment that both cures the infection and provides rapid symptom relief without at the same time causing the problematic side effects that today’s antibiotic treatments mean for both the individual and global health with the serious development of antibiotic resistance. The launch of Vernivia®, which is sold via pharmacy chains in Sweden, is the first step towards Pharmiva’s goal of becoming a global femtech company with a broad portfolio of antibiotic-free products in vaginal health. Pharmiva’s employees together have broad Life Science experience and knowledge in the field of therapy and product development.
The offer in summary
Record date: 7 September 2022
Subscription period: 12 September - 26 September 2022
Subscription rights: Anyone who is a shareholder in the Company on the record date of September 7, 2022 has preferential rights to subscribe for shares in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) subscription right. Three (3) subscription rights entitle the holder to subscribe for two (2) new shares.
Price: 1.80 SEK
The offer: 5 489 648 shares
Trading with rights: 12 September - 21 September 2022
Market place: Nasdaq First North Growth Market
Financial advisor: Sedermera Corporate Finance